HOUSTON, March 6,
2024 /PRNewswire/ -- FibroBiologics, Inc.
(Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage
biotechnology company with 150+ patents issued and pending with a
focus on the development of therapeutics and potential cures for
chronic diseases using fibroblasts and fibroblast-derived
materials, announced the appointment of Ruben A. Garcia as
General Counsel. He will report to Pete
O'Heeron, FibroBiologics' Founder, Chairman and Chief
Executive Officer, and be an integral member of the executive
leadership team.
"The addition of Ruben as our General Counsel represents a
significant milestone for FibroBiologics in its journey as a
publicly traded company," said Mr. O'Heeron. "His experience,
particularly in public company reporting and corporate governance
matters, healthcare compliance, and strategic and commercial
transactions, is a key addition. We believe Ruben's appointment
will enhance FibroBiologics' overall leadership and organizational
efficiency as well as help us advance our clinical and pre-clinical
pipelines."
"I am thrilled and honored to become a part of this
extraordinary team," said Mr. Garcia. "Arriving at such a pivotal
moment, I am confident that our collective capabilities and vision
will elevate FibroBiologics well."
Mr. Garcia brings more than 20 years of experience and an
extensive background in legal leadership positions in the
pharmaceutical industry. He most recently served as Senior Vice
President, General Counsel and Corporate Secretary at AcelRx
Pharmaceuticals, Inc. (n/k/a Talphera, Inc.). In that role, he was
responsible for all legal and compliance matters. Prior to his role
at AcelRx, Mr. Garcia served as Senior Corporate Counsel and
Assistant Secretary for Ultragenyx Pharmaceutical Inc. Mr. Garcia
began his legal career at Vinson & Elkins L.L.P. in
Houston before joining
Jones Day in Silicon Valley. He
earned his Juris Doctor from Stanford Law
School and his B.A. from Georgetown
University. Mr. Garcia is a member of the State Bars of
California and Texas.
For more information, please visit FibroBiologics' website or
email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning
FibroBiologics' advancement of its pipelines and the role to be
played by, and impact of, the General Counsel. These
forward-looking statements are based on FibroBiologics'
management's current expectations, estimates, projections and
beliefs, as well as a number of assumptions concerning future
events. When used in this communication, the words "estimates,"
"projected," "expects," "anticipates," "forecasts," "plans,"
"intends," "believes," "seeks," "may," "will," "should," "future,"
"propose" and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements. These forward-looking
statements are not guarantees of future performance, conditions or
results, and involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of
which are outside FibroBiologics' management's control, that could
cause actual results to differ materially from the results
discussed in the forward-looking statements, including those set
forth under the caption "Risk Factors" and elsewhere in
FibroBiologics' annual, quarterly and current reports (i.e., Form
10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC
and any subsequent public filings. Copies are available on the
SEC's website, www.sec.gov. These risks, uncertainties, assumptions
and other important factors include, but are not limited to: (a)
the ability of FibroBiologics to continue to meet Nasdaq listing
requirements; (b) risks related to FibroBiologics' liquidity and
its ability to maintain capital resources sufficient to conduct its
business; and (c) the ability to effectively manage the business as
a result of the super-voting proxy given to the Board of Directors.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and FibroBiologics assumes no obligation and, except as
required by law, does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. FibroBiologics gives no assurance that
it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy,
regenerative medicine company developing a pipeline of treatments
and potential cures for chronic diseases using fibroblast cells and
fibroblast-derived materials. FibroBiologics holds 150+ US and
internationally issued patents/patents pending across various
clinical pathways, including disc degeneration, orthopedics,
multiple sclerosis, psoriasis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic
Johnson or Harrison Seidner,
Ph.D.
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz
Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-appoints-ruben-a-garcia-as-general-counsel-302080882.html
SOURCE FibroBiologics